Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29100626
Abstract: Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib,… read more here.
Keywords: intrahepatic cholangiocarcinoma; progress; cholangiocarcinoma; work progress ... See more keywords